Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
The present invention provides methods for treating and preventing benign breast disease by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with benign breast disease, this effect induces disease regression. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents formation of benign breast conditions that can lead to cancer.
1. A method of treatment, comprising percutaneously administering an effective amount of 4-hydroxy tamoxifen to a female patient having benign breast disease, wherein said 4-hydroxy tamoxifen is in a vehicle containing an effective amount of isopropyl myristate as a fatty acid ester penetration enhancer, wherein said benign breast disease is selected from the group consisting of adenosis, cysts, duct ectasia, fibroadenoma, fibrocystic disease, fibrosis, hyperplasia and metaplasia and wherein said vehicle is a hydroalcoholic gel or hydroalcoholic solution that comprises (a) about 0.001 % to 1.0 % by weight of 4-hydroxy tamoxifen, (b) about 0.5% to 2% by weight of isopropyl myristate, (c) about 60% to 75% by weight of absolute alcohol, (d) about 25% to 40% by weight of aqueous vehicle, and (e) about 0.5% to 5% by weight of gelling agent, wherein the percentage of components are weight to weight of the gel or solution.
2. The method according to claim 1 , wherein about 0.25 to 2.0 mg/breast of said 4-hydroxy tamoxifen is administered to said patient per day.
3. The method according to claim 1 , wherein about 0.5 to 1.0 mg/breast of said 4-hydroxy tamoxifen is administered to said patient per day.
4. The method according to claim 1 , wherein about 0.25 mg/breast of said 4-hydroxy tamoxifen is administered to said patient per day.
5. The method according to claim 1 , wherein about 0.5 mg/breast of said 4-hydroxy tamoxifen is administered to said patient per day.
6. The method according to claim 1 , wherein about 0.75 mg/breast of said 4-hydroxy tamoxifen is administered to said patient per day.
7. The method according to claim 1 , wherein about 1.0 mg/breast of said 4-hydroxy tamoxifen is administered to said patient per day.
8. The method according to claim 1 , wherein said 4-hydroxy tamoxifen is formulated in a hydroalcoholic gel.
9. The method according to claim 1 , wherein said hydroalcoholic gel or hydroalcoholic solution comprises a neutralizing agent.
10. The method according to claim 1 , wherein said 4-hydroxy tamoxifen constitutes about 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.10%, 0.11%, 0.12%, 0.13%, 0.14%, 0.15%, 0.16%, 0.17%, 0.18%, 0.19% or 0.20% by weight of the hydroalcoholic gel or hydroalcoholic solution.
11. The method according to claim 1 , wherein said isopropyl myristate constitutes about 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9% or 2.0% by weight of the hydroalcoholic gel or hydroalcoholic solution.
12. The method according to claim 1 , wherein said alcohol is ethanol or isopropanol, and constitutes in absolute form about 60% to 75% by weight of the hydroalcoholic gel or hydroalcoholic solution.
13. The method according to claim 1 , wherein said aqueous vehicle is a phosphate buffered solution, and constitutes about 25% to 40% by weight of the hydroalcoholic gel or hydroalcoholic solution.
14. The method according to claim 1 , wherein said gelling agent is a polyacrylic acid, hydroxypropylcellulose or other type of cellulose, and constitutes about 0.5% to 5% by weight of the hydroalcoholic gel or hydroalcoholic solution.
15. The method according to claim 1 , wherein said hydroalcoholic gel or hydroalcoholic solution further comprises a neutralizing agent selected from the group consisting of sodium hydroxide, ammonium hydroxide, potassium hydroxide, arginine, aminomethylpropanol, trolamine and tromethamine, which neutralizing agent is present at a neutralizing agent/gelling agent ratio of between 4:1 and 1:1.
16. The method according to claim 1 , wherein said hydroalcoholic gel or hydroalcoholic solution is packaged in a unit dose packet or in a multiple dose container with a metered pump.
17. The method according to claim 1 , wherein said benign breast disease is a proliferative breast disease.
18. The method according to claim 1 , wherein said benign breast disease has an estrogen-related component.
19. The method according to claim 1 , wherein said patient is pre-menopausal.